Cytosolic phospholipase A 2-α: A potential therapeutic target for prostate cancer

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8070-8079

  Patel, Manish I ^a,b   Singh, Jaskirat ^a,c   Niknami, Marzieh ^a,c   Kurek, Caroline ^a,c   Yao, Mu ^a,c   Lu, Sasa ^a,c   Maclean, Fiona ^d   King, Nicholas J C ^a   Gelb, Michael H ^g   Scott, Kieran F ^e   Russell, Pamela J ^f   Boulas, John ^c   Dong, Qihan ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d Douglas Hanley Moir Pathology   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f PRINCE OF WALES HOSPITAL   (Australia)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYTOSOLIC PHOSPHOLIPASE A2 ALPHA; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WYETH 1; CCND1 PROTEIN, HUMAN; ENZYME INHIBITOR; PHOSPHOLIPASE A2 GROUP IV;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CYTOSOL; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYTOSOL; ENZYME INHIBITORS; GROUP IV PHOSPHOLIPASES A2; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 58149340586     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0566     Document Type: Article

References (49)

1. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-51.
2. Patel MI, Kurek C, Dong Q. The arachidonic acid pathway and its role in prostate cancer development and progression. J Urol 2008;179:1668-75.
3. Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM. HER2 and COX2 expression in human prostate cancer. Eur J Cancer 2004;40:50-5.
4. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is over-expressed in prostate adenocarcinoma. Cancer 2001;91:737-43.
5. Kelavkar U, Cohen C, ElingT, Badr K. 15-Lipoxyge-nase-1 overexpression in prostate adenocarcinoma. Adv Exp Med Biol 2002;507:133-45.
6. Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 2001;21:1291-4.
7. Matsuyama M,Yoshimura R, Mitsuhashi M, et al. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol 2004;24:821-7.
8. Nie D, Che M, Grignon D, Tang K, Honn KV. Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev 2001;20:195-206.
9. Nie D,Hillman GG, Geddes T, et al. Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 1998;58:4047-51.
10. Pidgeon GP, Kandouz M, Meram A, Honn KV. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res 2002;62:2721-7.
11. Fujishima H, Sanchez Mejia RO, Bingham CO III, et al. Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells. Proc Natl Acad Sci U S A1999;96:4803-7.
12. Laye JP, Gill JH. Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discov Today 2003;8:710-6.
13. Chetcuti A, Margan SH, Russell P, et al. Loss of Annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 2001;61:6331-4.
14. Sved P, Scott KF, McLeod D, et al. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res 2004;64:6934-40.
15. Ni Z, Okeley N, Smart B, Gelb MH. Intracellular actions of group IIA secreted phospholipase A2 and group IVA cytosolic phospholipase A2 contribute to arachidonic acid release and prostaglandin production in rat gastric mucosal cells and transfected human embryonic kidney cells. J Biol Chem 2006;281:16245-55.
16. Mounier CM, Ghomashchi F, Lindsay MR, et al. Arachidonic acid release from mammalian cells trans-fected with human groups IIA and X secreted phos-pholipase A(2) occurs predominantly during the secretory process and with the involvement of cyto- solic phospholipaseA(2)-α. J Biol Chem 2004;279:25024-38.
17. Patel MI, Tuckerman R, Dong Q. A pitfall of the 3-(4,5-dimethylthiazol-2- yl)-5(3-carboxymethony-phenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay due to evaporation in wells on the edge of a 96 well plate. Biotechnol Lett 2005;27:805-8.
18. Patel MI, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclo-oxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999-2007.
19. Gorovetz M, Baekelandt M, Berner A, Trope CG, Davidson B, Reich R. The clinical role of phospholi-pase A(2) isoforms in advanced-stage ovarian carcinoma. Gynecol Oncol 2006;103:831-40.
20. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer1997;75:1111-8.
21. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor cele-coxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-403.
22. Liu XH, Kirschenbaum A,Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-5.
23. Anderson KM, Seed T,Vos M, et al. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate1998;37:161-73.
24. Gao X, Grignon DJ, Chbihi T, et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology1995;46:227-37.
25. Timar J, RasoE,Dome B,et al. Expression, subcellular localization and putative function of platelet-type12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int J Cancer 2000;87:37-43.
26. Hoeck WG, Ramesha CS, Chang DJ, Fan N, Heller RA. Cytoplasmic phospholipaseA2 activity and gene expression are stimulated by tumor necrosis factor: dexamethasone blocks the induced synthesis. Proc Natl Acad Sci U S A1993;90:4475-9.
27. Jackson BA, Goldstein RH, Roy R, Cozzani M, Taylor L, Polgar P. Effects of transforming growth factor β and interleukin-1 βon expression of cyclooxyge-nase 1 and 2 and phospholipase A2 mRNA in lung fibroblasts and endothelial cells in culture. Biochem Biophys Res Commun 1993;197:1465-74.
28. Hughes-Fulford M,Tjandrawinata RR, Li CF,Sayyah S. Arachidonic acid, an ω-6 fatty acid, induces cyto-plasmicphospholipase A2 in prostate carcinoma cells. Carcinogenesis 2005;26:1520-6.
29. Lappas M, Permezel M, Georgiou HM, Rice GE. Regulation of phospholipase isozymes by nuclear factor-κB in human gestational tissues in vitro. J Clin Endocrinol Metab 2004;89:2365-72.
30. Palayoor ST,Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibu-profen. Oncogene1999;18:7389-94.
31. Fleshner N, Bagnell PS, Klotz L,Venkateswaran V. Dietary fat and prostate cancer. J Urol 2004;171:S19-24.
32. Fleshner N, Fair WR, Huryk R, Heston WD.Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol 1999;161:1651-4.
33. Kang JS, Calvo BF, Maygarden SJ, Caskey LS, Mohler JL, Ornstein DK. Dysregulation of Annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin Cancer Res 2002;8:117-23.
34. Burger M, Denzinger S, Hammerschmied C, et al. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Eur Urol 2006;50:1102-9.
35. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993;72:269-78.
36. Geijsen N, Dijkers PF, LammersJJ, Koenderman L, Coffer PJ. Cytokine-mediated cPLA(2) phosphorylation is regulated by multiple MAPK family members. FEBS Lett 2000;471:83-8.
37. Hernandez M, Burillo SL, Crespo MS, Nieto ML. Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1. J Biol Chem 1998;273:606-12.
38. Han WK, Sapirstein A, Hung CC, Alessandrini A, Bonventre JV. Cross-talk between cytosolic phospho-lipase A2 α (cPLA2 α) and secretory phospholipase A2 (sPLA2) in hydrogen peroxide-induced arachi-donic acid release in murine mesangial cells: sPLA2 regulates cPL A2 α activity that is responsible for arachidonic acid release. J Biol Chem 2003;278:24153-63.
39. Ono T,Yamada K, Chikazawa Y, et al. Characterization of a novel inhibitor of cytosolic phospholipase A2α, pyrrophenone. Biochem J 2002;363:727-35.
40. Nesterov A, Lu X, Johnson M, Miller GJ, Ivash-chenkoY, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001;276:10767-74.
41. Kulp SK,Yang YT, Hung CC, et al. 3-phosphoinosi-tide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004;64:1444-51.
42. Seo KH, Lee HS, Jung B, et al. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-κB activation. Cancer Res 2004;64:6482-8.
43. Axelrad TW, Deo DD, Ottino P, et al. Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. FASEB J 2004;18: 568-70.
44. Bussolati B, Biancone L, Cassoni P, et al. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angio-genesis. Am J Pathol 2000;157:1713-25.
45. Osterstrom A, Dimberg J, Fransen K, Soderkvist P. Expression of cytosolic and group X secretory phos-pholipaseA(2) genes in human colorectal adenocarcinomas. Cancer Lett 2002;182:175-82.
46. Soydan AS,Tavares IA, Weech PK,Tremblay NM, Bennett A. High molecular weight phospholipase A2: its occurrence and quantification in human colon cancer and normal mucosa. Adv Exp Med Biol 1997;400A:31-7.
47. Hong KH, Bonventre JC, O'Leary E, Bonventre JV, Lander ES. Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc Natl Acad Sci U S A2001;98:3935-9.
48. Dong M, Guda K, Nambiar PR, et al. Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 2003;24:307-15.
49. IlsleyJN,NakanishiM,FlynnC,etal.Cytoplasmic phospholipase A2 deletion enhances colon tumori-genesis. Cancer Res 2005;65:2636-43.